Acino ? Delivering Health

More documents

Recommendations

Info

Reduced currency exposure Mepha / Cephalon acquisition leads to reduced FX exposure - Sales in CHF: FY 2011 nearly 0%, H1-2012 increase to 15% - Sales in USD or related currencies: FY 2011 0%, H1-2012 24% - Operating Expenses in USD or related currencies: FY 2011 0%, H1-2012 27% Amended natural hedge 86
Acino – Delivering Health Thank you for your attention 87
Page 1 and 2:
Acino - Delivering Health Investor
Page 3 and 4:
Acino - drug delivery specialist, m
Page 5 and 6:
Acino’s growth drivers Fully expl
Page 7 and 8:
Technology platform Oral modified r
Page 9 and 10:
Oral modified release forms MUPS (M
Page 11 and 12:
Technology platform Oral dispersibl
Page 13 and 14:
Technology platform Transdermal sys
Page 15 and 16:
Transdermal systems Why transdermal
Page 17 and 18:
Technology platform Extended releas
Page 19 and 20:
Extended release parenterals Advant
Page 21 and 22:
Development projects Ferrous sulfat
Page 23 and 24:
Development projects Rivastigmine T
Page 25 and 26:
Development projects Goserelin & le
Page 27 and 28:
Development projects Goserelin 1 &
Page 29 and 30:
Development projects Leuprorelin 1
Page 31 and 32:
Acino’s development pipeline Stat
Page 33 and 34:
Acino - Delivering Health Thank you
Page 35 and 36: Entering emerging markets / “Swis
Page 37 and 38: Acino Switzerland 2009 BtC markets
Page 43 and 44: Opportunities Products with added v
Page 45 and 46: Acino Switzerland: Product Portfoli
Page 47 and 48: Acino portfolio Roll-out in new ter
Page 49 and 50: Criteria for selecting products for
Page 51 and 52: Acino’s business model (example)
Page 53 and 54: Optimized BtB Concept - Geographica
Page 55 and 56: Technical Marketing and Operations:
Page 57 and 58: Acino’s production importance Tec
Page 59 and 60: Production Technologies: Value for
Page 61 and 62: Pellets Innovative technologies for
Page 63 and 64: Pellet Projects High volume project
Page 65 and 66: Granulates Hot melt granulation Sp
Page 67 and 68: Manufacturing Process 67
Page 70 and 71: Implants Implant manufacturing capa
Page 72 and 73: Opportunity: High Quality Service S
Page 74 and 75: Summary Focus on niche technologies
Page 76 and 77: Competitive advantage factor: HighT
Page 78 and 79: Micro Error Tracking System (METS)
Page 80 and 81: Strategy to cope with declining mar
Page 82 and 83: Financials Robert Schmid, Head of I
Page 84 and 85: Promising potential areas of synerg
Page 88 and 89: Summary and strategy Peter Burema,
Page 90 and 91: Acino’s growth drivers Fully expl
Page 92 and 93: Geographic break-down of revenue DE
Page 94: Acino - Delivering Health Thank you
show all

Acino ? Delivering Health

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?